KAWASAKI, Japan, May 29, 2026 - (JCN Newswire) - Fujitsu Limited today announced the launch of "Fujitsu Sustainability Disclosure Navigator," a new service under its Sustainable Finance offering within "Uvance for Finance". This service leverages AI to analyze non-financial information disclosure, helping companies organize and manage disclosure content based on ESG evaluation criteria and make decisions on disclosure policies that contribute to enhanced corporate value.

The service, available from May 29, 2026, utilizes Fujitsu's own expertise in non-financial information disclosure and AI to analyze and manage non-financial information, benchmark disclosure content against over 1,000 listed companies in Japan, and enable disclosure that considers ESG evaluations. This will allow companies to strategically disclose non-financial information, aiming for inclusion in ESG indices and other capital market considerations. Through this service, Fujitsu aims to support companies in their continuous value creation and contribute to the revitalization of the domestic stock market.

Background 

In 2023, the Tokyo Stock Exchange issued a request for companies to focus on "realizing management that is conscious of capital costs and stock prices," increasing the importance of information disclosure for enhancing corporate value. While many companies are expanding their disclosure information in response, they face challenges in organizing required disclosure items, objectively understanding their disclosure levels and positioning compared to competitors, and benchmarking due to the increasing complexity of non-financial information disclosure requirements. As a result, significant time and effort are required to achieve disclosure that leads to positive evaluations, and internal information management systems are often not adequately prepared, leading to a tendency for tasks to become individualized. 

Overview of "Fujitsu Sustainability Disclosure Navigator" 

This service uses AI to objectively analyze the presence and status of non-financial information disclosure by a company and its competitors, based on the evaluation criteria of multiple ESG rating agencies, thereby supporting companies in achieving evaluations that reflect their actual performance. It also provides analysis and insights for improving future ESG evaluations, supporting the strategic disclosure of non-financial information. The AI leverages knowledge accumulated through Fujitsu's own long-standing practice of non-financial information disclosure, as well as non-financial information publicly disclosed by over 1,000 listed companies in Japan, including Fujitsu. Fujitsu aims to continuously improve the service's functions through agile development even after its launch, providing comprehensive support for non-financial information disclosure.

Figure: Conceptual diagram of the "Fujitsu Sustainability Disclosure Navigator"

Features of "Fujitsu Sustainability Disclosure Navigator" 

1. Visualization of compliance with the latest ESG evaluation criteria

The service organizes and visualizes the disclosure content required of a company, taking into account the latest trends in ESG evaluation criteria emphasized by ESG rating agencies.

It also centrally manages non-financial information across multiple disclosure media, such as integrated reports and annual securities reports, preventing omissions and inconsistencies in information when updating disclosure media and significantly reducing the time and effort required for research and verification.

2. Clarification of a company's position and differentiation points through comparative analysis

By using AI to organize the presence and content of non-financial information disclosure from over 1,000 listed companies in Japan and efficiently referencing disclosure sections related to ESG evaluations, companies can understand their disclosure levels and differentiation points compared to competitors, enabling strategic information disclosure planning. 

3. Support system leveraging technology and expert knowledge 

In non-financial information disclosure, it can be difficult for a company to determine "what, to what extent, and how to disclose" on its own, considering the perspectives of evaluation agencies and multiple disclosure standards.

This service will also offer advisory services related to ESG information disclosure based on expertise provided by professionals from Deloitte Tohmatsu LLC, combining technology and expert knowledge to support customers in creating high corporate value.

Fujitsu also plans to further enhance various AI-powered functions, including the generation of disclosure draft documents.

Future Plans

Moving forward, Fujitsu will evolve this service to not only streamline and advance non-financial information disclosure but also to support decision-making directly linked to corporate value enhancement. Specifically, Fujitsu aims to expand functions for analyzing the relationship and causality between financial indicators such as ROIC and PBR and non-financial activities, as well as functions to support dialogue with investors.

Furthermore, Fujitsu will strengthen AI-powered support functions for overall non-financial information disclosure operations and expand its ecosystem through co-creation with partner companies possessing diverse expertise, including ESG rating agencies. Through the "Uvance for Finance" offering, Fujitsu aims to contribute to the enhancement of customer corporate value and, in turn, to the revitalization of the entire Japanese economy.

Through "Uvance for Finance", Fujitsu will also advance the sustainability of society and the economy by leveraging data and AI to enhance non-financial information disclosure for companies and corporate evaluations for financial institutions, thereby improving both corporate and asset value.

Fujitsu’s Commitment to the Sustainable Development Goals (SDGs)

The Sustainable Development Goals (SDGs) adopted by the United Nations in 2015 represent a set of common goals to be achieved worldwide by 2030.

Fujitsu’s purpose — “to make the world more sustainable by building trust in society through innovation” — is a promise to contribute to the vision of a better future empowered by the SDGs.

About Fujitsu

Fujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 100,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.5 trillion yen (US$23 billion) for the fiscal year ended March 31, 2026 and remains the top digital services company in Japan by market share. Find out more: global.fujitsu

Press Contacts

Fujitsu Limited
Public, Investor and Analyst Relations Division
Inquiries 

SHANGHAI, May 29, 2026 - (ACN Newswire) - Sigenergy today introduced SigenAgent, the energy industry’s first all-domain AI agent, fundamentally changing how households and businesses interact with renewable energy.

Unveiled during the company’s "AI in All" event, SigenAgent elevates solar-and-storage hardware from basic, reactive equipment into autonomous, goal-driven systems.

As global energy dynamics transition from power generation to complex, volatile consumption models, manual management has hit its limit. SigenAgent solves this by allowing hardware to actively interpret and execute broad user goals.

"True AI is not just a chatbot companion," said Tony Xu, Founder and CEO of Sigenergy. "It is a partner that understands your goals, executes tasks on your behalf, and continuously learns over time."

The Vision: User Sets the Goal, AI Handles the Rest

SigenAgent operates on a continuous loop of perception, reasoning, and action. By synthesizing real-time factors like weather patterns, fluctuating electricity prices, and grid conditions, it automatically charts and executes the most efficient operational path.

To deliver complete energy management, SigenAgent deploys four specialized, autonomous capabilities:

Energy Manager: Brings "autonomous driving" to home solar-and-storage systems. Users simply set macro targets—such as lowering utility bills or securing backup power—and the system automatically configures and runs the hardware.

System Doctor: Replaces manual logs with "second-level diagnosis." A single command triggers an immediate, station-wide scan that pinpoints system anomalies and reports root causes, drastically lowering maintenance overhead.

Power Trader: Maximizes revenue for storage assets in highly volatile, high-frequency electricity markets by optimizing real-time trading and Virtual Power Plant (VPP) responses.

Business Assistant: Links directly to enterprise data lakes to dissolve information silos across production and delivery, providing clear, data-driven operational recommendations.

Built on a Foundation of Hardware and Safety

SigenAgent is not an isolated software patch, but the culmination of Sigenergy's long-term hardware and software integration. CEO Tony Xu emphasized that AI in energy requires more than algorithms; it demands a reliable physical foundation.

Today, over 200,000 global power stations run on Sigenergy hardware. Built on this bedrock, Sigenergy utilizes all-domain sensing across generation, storage, charging, and grid access—supported by 100M high-speed networks, WLAN-Mesh, and Sub-1G communications to create a seamless, closed-loop operational environment.

Thanks to an AI-ready architecture, existing operational units can access these agent features via seamless over-the-air (OTA) software updates.

While granting execution capabilities to AI, the system enforces strict architectural boundaries to guarantee safety and user trust:

User Authorization: SigenAgent operates strictly as an assistant, requiring explicit user approval for critical parameter changes.

Secure Infrastructure: Localized data storage across six global data centers ensures absolute compliance with regional privacy laws.

Offline Resilience Guaranteed: Pre-programmed dynamic backup strategies ensure the system continues to run smoothly even during network outages.

Transparent AI Decision: A fully transparent user interface eliminates the "AI black box," mapping out exactly why a system is charging or discharging over a 24-hour window.

SigenAgent is designed to meet users where they are, integrating seamlessly into common workflows and messaging applications like WhatsApp and Telegram.

Standardizing the Intelligence Era

To help define this new era of energy, Sigenergy collaborated with Frost & Sullivan to publish the 2026 AI-Powered New Energy White Paper.

The report outlines the Energy Intelligence Level (EIL) framework—a five-tier classification system modeled after autonomous driving standards—designed to guide the industry's transition from individual device intelligence to fully autonomous, system-wide optimization.

"What Sigenergy is delivering today is not just a product, or a tech upgrade—we are delivering a completely new energy lifestyle," said Xu. "Users can optimize every kilowatt-hour without needing to understand complex technical details. Energy systems are shifting from passive hardware into active companions."

About Sigenergy

Founded in 2022 and headquartered in Shanghai, Sigenergy (6656.HK) is a technology-driven company focused on innovation in the new energy sector. Leveraging advanced digital intelligence and a highly skilled talent base, the company has expanded across photovoltaic (PV) generation, smart energy storage, and high-efficiency electric vehicle (EV) charging solutions.

Guided by its “AI in All” strategy, Sigenergy integrates artificial intelligence across its product ecosystem to deliver safer, smarter and more efficient energy solutions for households and businesses worldwide.

For more information, visit: www.sigenergy.com

Media Contact

Tracy Li
Email: tracy.li@sigenergy.com

According to Frost & Sullivan, the global autoimmune disease drug market is expanding steadily, estimated to increase from US$138.9 billion in 2024 to US$176.7 billion in 2030, with a CAGR of 4.1%. By contrast, China’s market demonstrates explosive growth momentum. The market size in China is estimated to surge from US$5.1 billion in 2024 to US$19.0 billion in 2030, with a remarkable CAGR of 24.5%, far outpacing the global average and embracing vast market opportunities.

LongBio Pharma (Suzhou) Co., Ltd. ("Longbio Pharma" or the "Company", Stock Code: 01779.HK), a leading player in the sector, officially launched its Public Offering on 28 May, marking the final countdown to its Hong Kong listing. The Company is poised to embark on a new chapter of commercialisation and scaled development empowered by the capital market. 

Focused on Premium Therapeutic Track, Premium Innovative Pipeline Builds Core Barriers

Founded in 2020, Longbio Pharma is a clinical-stage innovative biopharmaceutical company with full in-house capabilities for drug discovery and development, focusing on allergic and autoimmune diseases. Since inception, the Company has consistently prioritised unmet clinical needs and specialised in differentiated innovative tracks, building a well-structured, tiered and high-potential innovative product pipeline.

The Company has established a three-tier product layout featuring breakthrough core product + leading flagship product + robust pipeline reserves. Its portfolio includes core product LP-003 and flagship product LP-005, alongside multiple innovative drug candidates covering high-value indications such as allergic diseases and complement-mediated autoimmune diseases, underpinning promising long-term growth prospects.

Longbio Pharma’s core product LP-003 is a differentiated Anti-IgE monoclonal antibody with an innovative sequence design. It precisely targets the core pathogenesis of allergic diseases, indicated for the targeted treatment of seasonal allergic rhinitis (AR), chronic spontaneous urticaria (CSU), allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and food allergies. Its primary function is to specifically block free IgE in human blood and tissues, and thus inhibiting the occurrence of IgE-driven allergic reactions.

Compared with conventional therapies, LP-003 efficiently binds to free IgE and prohibits those excessive IgEs from binding to the high-affinity IgE receptor, FcεRI. Boasting a precise mechanism of action, strong targeting capability and a broad spectrum of indications, it delivers distinct competitive edges and substantial market potential. 

Clinical data have fully validated its robust product strength. As at the Latest Practicable Date, Longbio Pharma has initiated eight clinical trials in China for LP-003, of which two have been completed and the other six are still ongoing. Top-line results from the Phase II clinical trial for CSU showed that LP-003 demonstrated promising efficacy (fast onset of action, good efficacy and long-acting) compared to omalizumab in the treatment of CSU. LP-003 also showed favorable efficacy and safety profile in its Phase II clinical trial for moderate-to-severe seasonal AR that is inadequately controlled by standard treatment. A Phase III clinical trial for the treatment of seasonal AR is currently underway in China.

With the steady advancement of clinical trials and continuous release of key clinical data, LP-003 is expected to reshape the treatment landscape for allergic diseases and fill the domestic market gap for high-efficiency, long-acting differentiated anti-IgE drugs. Upon commercialisation, it is set to capture a substantial share of the allergic disease treatment market and become a core driver of the Company’s performance growth.

LP-005, the Company’s flagship product, is the first innovative drug developed on its Bi-functional Antibody Development Platform and a bi-functional antibody fusion protein targeting C5 and C3b complement. By acting on multiple key nodes in the complement cascade simultaneously, it comprehensively blocks complex pathological mechanisms of diseases and achieves synergistic multi-pathway inhibition. Outperforming conventional single-target drugs in therapeutic potential and indication coverage, it boasts prominent technological and clinical value.

LP-005 has obtained IND approvals in China for various indications, including paroxysmal nocturnal hemoglobinuria (PNH), complement-mediated kidney diseases (including but not limited to IgAN, C3G and LN), and other complement related indications, covering a range of major diseases with high clinical demand and limited curative options.

The Company is steadily advancing several clinical trials of LP-005 for PNH and complement-mediated kidney diseases. Interim data from Phase II clinical trial (CTR20242478) have yielded encouraging results. From the data collected, LP-005 has shown encouraging efficacy in PNH patients, including two PNH patients who were previously treated with omalizumab but inadequately controlled, still have benefitted continuously from LP-005 treatment throughout the trial period. LP-005 demonstrated favorable safety and tolerability in the Phase I study in China involving healthy subjects, laying a solid foundation for subsequent large-scale clinical development and commercial application.

With continuous breakthroughs in clinical trials, LP-005 is expected to become China’s first novel multi-target complement drug, filling the huge unmet medical need for refractory autoimmune diseases and securing a first-mover advantage in the complement inhibitor segment. It will open up a new growth curve for the Company.

While advancing its core and flagship products, Longbio Pharma continues to expand its pipeline reserves to sustain long-term growth. The Company has developed multiple promising candidates, including LP-00A, a bi-functional autoimmune antibody targeting allergic diseases, LP-00C, a bi-functional B-cell inhibitor targeting B-cell mediated autoimmune diseases and LP-00D, a bi-functional antibody or fusion protein complement inhibitor optimized for specific tissues/organs and indications. The diversified pipelines currently in development precisely target segmented disease areas, forming a rich and diverse pipeline that underpins the Company’s sustained innovation and steady growth.

Self-developed Technology Platforms Empower R&D Strength for Long-term Innovation

Innovative technology platforms are the cornerstone for biopharmaceutical enterprises to continuously deliver high-quality pipelines. With years of expertise in innovative drug R&D, Longbio Pharma has built two proprietary, industry-leading technology platforms: the High-Affinity Antibody Discovery Platform and the Bi-functional Antibody Development Platform. Supported by standardised and systematic R&D workflows, the platforms empower the entire process of candidate drug early discovery and structural optimisation, establishing a solid technical barriers.

The two core R&D platforms cover key links across the biologic drug development value chain. They enable early identification and mitigation of potential risks in clinical development and industrial production. Leveraging platform strengths, the Company efficiently screens high-value candidates with clinical value, cost advantages and commercial potential, achieving optimal allocation of R&D resources and sustainable delivery of premium pipeline products.

The High-Affinity Antibody Discovery Platform features industry-leading antibody screening and optimisation capabilities. Compared with conventional R&D technologies, it significantly enhances the targeting affinity, specificity and stability of antibody drugs. LP-003, developed via this platform, achieves iterative superiority over traditional analogue drugs in efficacy and targeting performance, validating the platform’s technological advancement and reliability.

The Bi-functional Antibody Development Platform breaks the structural limitations of conventional single-target antibodies. It features structural flexibility, broad applicability, high druggability and strong scalability, enabling rapid development of multi-target and multi-mechanism innovative drugs to address complex autoimmune conditions. Pipeline candidates including LP-005, LP-00A, LP-00C and LP-00D are all developed on this platform, demonstrating its robust sustainable output capacity.

Backed by its proprietary core technology platforms, Longbio Pharma has built an proprietary innovative drug R&D system, covering target discovery, molecular optimisation, preclinical research and clinical development. The Company has achieved full independence in R&D and freed itself from external technological reliance. Supported by favourable industry policies, expanding market demand and continuous technological breakthroughs, the Company’s pipeline value keeps unlocking with clear growth logic and strong momentum.

Overall, Longbio Pharma is strategically positioned in the high-growth autoimmune and allergy track. With a portfolio of differentiated core candidates and self-built cutting-edge R&D platforms, it has established solid and profound competitive barriers.

Following its Hong Kong listing, the Company will leverage capital market resources to accelerate the translation of innovative achievements and expand industrial boundaries. It is well-positioned to continuously capture market opportunities in segmented sectors, fully unlock growth potential and boast promising long-term development prospects.

SINGAPORE, May 29, 2026 - (ACN Newswire) - Life in Singapore often brings unexpected costs that can sometimes deter even the best financial plans. While it is tempting to see a credit line as extra disposable income for non-essential lifestyle choices, the most responsible way to use standby cash is to create a safety net for unplanned costs.

Having a credit facility ensures you can handle urgent needs without disturbing your long-term savings or selling your investments at a loss, if you use it prudently and be mindful of the applicable interest, fees and repayment obligations. Here are five smart ways to use your standby funds for emergencies.

Urgent home repairs

A home is often your largest asset, but it requires constant upkeep. A sudden burst pipe, a leaking ceiling, or a faulty electrical circuit is more than just an everyday inconvenience; it is a threat to your property's value. If you do not fix these issues immediately, they can lead to mould, water damage, or even fire hazards.

Most contractors in Singapore require an upfront deposit or immediate payment upon completion. These costs often fall outside your regular monthly budget. In such cases, using your standby cash allows you to hire a professional right away. This prevents a small, manageable repair from turning into a massive renovation bill that could otherwise cause you a significant financial loss in the future.

Managing non-insured healthcare costs

Residents of Singapore generally have good insurance coverage through MediShield Life (a lifelong national health insurance scheme in Singapore) or other private plans. However, insurance may not always cover all medical circumstances. For example, a sudden dental emergency like a fractured tooth or a painful abscess requires immediate treatment. Outpatient specialist visits or specific diagnostic tests may also require you to pay in cash first before you can claim them back.

In a medical crisis, time is of the essence. One should not have to wait until the next payday to seek relief from pain or to get a necessary scan. Having standby cash ready means you can walk into a clinic or hospital, thus ensuring you receive the care you need without the added stress of checking your bank balance during a health scare.

Bridging income gaps during retrenchment

Retrenchment is a sudden loss of income that can take place regardless of your industry or experience level. In a competitive job market, it can typically take between three to six months to secure a new role that matches your previous salary.

While a dedicated emergency fund is ideal, it may not always cover the full duration of your unemployment. In such cases, standby cash acts as a vital secondary buffer. It helps you cover essential monthly commitments temporarily, such as utility bills, and insurance premiums, thus allowing you to focus on your job search. This prevents you from falling behind on payments, which could otherwise damage your credit score.

Critical family emergencies

Family needs often arise without warning. A parent might face sudden hospitalisation, or a relative might need urgent financial help due to an unexpected crisis. These situations are emotionally draining and may often require immediate access to cash.

If your wealth is tied up in stocks, bonds, or unit trusts, you might be forced to sell them during a market downturn to get the cash you need. This locks in your losses and hurts your long-term retirement goals. Therefore, using standby cash provides the liquid funds needed in such emergencies. This allows your investments time to recover and continue growing, protecting your future wealth while you handle the present crisis.

Replacement of essential appliances

Home appliances often go unnoticed until they stop working. If your refrigerator dies in the middle of a humid Singaporean week, your food can spoil within hours. Similarly, a broken washing machine can quickly disrupt a busy household's routine.

Replacing these essential items can sometimes cost a significant amount of money. While it might be momentarily feasible to buy the cheapest model available to save money, it is often smarter to use standby cash to buy a high-quality, energy-efficient replacement. Quality appliances last longer and save you money on electricity bills, making them a better financial choice in the long run.

How to restore your safety net

Using standby cash responsibly means having a clear plan to pay it back. When you repay the amount you borrowed, that credit limit becomes available for you to use again for the next potential emergency.

Create a repayment schedule: As soon as the emergency is over, look at your monthly budget. Determine how much you can repay each month to clear the balance quickly.

Prioritise high-interest debt: If you have multiple debts, focus on paying off the used standby cash to minimise interest costs.

Use bonuses or windfalls: If you receive a work bonus or a tax refund, use a portion of it to renew your credit line.

Final thoughts

The value of standby cash lies in its role as a short-term financial buffer when used responsibly. It is not designed for lifestyle upgrades or impulsive shopping. Instead, it is there to give you peace of mind and protection. By reserving these funds for unplanned essential needs, you can protect your savings and ensure that a temporary crisis does not become a permanent financial setback.

Disclaimer: This content is published by iQuanti Singapore Pte Ltd, an external marketer engaged and compensated by UOB Ltd.

Contact Information:
Name: Sonakshi Murze
Email: Sonakshi.murze@iquanti.com
Job Title: Manager

SOURCE: iQuanti

HONG KONG, May 29, 2026 - (ACN Newswire) - Modern Dental Group Limited ("Modern Dental" or "the Group", stock code: 03600.HK), a leading global dental prosthetic devices provider, announced its operational data for the three months ended 31 March 2026.

During the three months ended 31 March 2026, the Group’s multi-dimensional strategies as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenue during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures, trade war and geopolitical uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.

Global Revenue

For the three months ended 31 March 2026, the total revenue of the Group increased by approximately 12.1% (approx. HK$987.5 million) compared with the three months ended 31 March 2025.

^ The decrease in revenue in original currency of the North America market (ex-MicroDental) was approximately 2.3% and the decrease in revenue in original currency of MicroDental was approximately 14.6%.

# The increase in revenue in original currency of the Mainland China market was approximately 1.5% and the decrease in revenue in original currency of Hong Kong market was approximately 3.7%.

++ The percentage change in Others represented changes in value of Hong Kong Dollars as Others included revenue dominated in different currencies.

* The revenue information above is based on the locations of the customers.

** The conversion rate shall not be taken as a representation that respective original currency could actually be converted into HK$ at that rate, or at all.

The increase in revenue in Europe was primarily driven by higher sales order volumes, supported by the successful launch of new products such as digital dentures and the rollout of our state-of-the-art digital workflows. As a frontrunner in providing comprehensive digital solutions — ranging from minimally invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners — the Group is well positioned to capitalize on the accelerated digitalization trend within the dental industry.

Revenue from MicroDental, our North American domestic dental laboratory business, declined due to the softer US economy, which led to reduced patient demand for high-value discretionary dental treatments, particularly implants. 

The Group’s revenue in the Mainland China market recorded 1.5% increase in original currency terms during the first quarter of 2026, representing a turnaround from the decline of 4.2% in 2025. The decrease in revenue in the Hong Kong market also narrowed to 3.7%, as compared to the decline of 11.5% in 2025.

The Mainland China market appears to have reached the bottom of the impact from the volume-based procurement policies and a prolonged period of intense price competition. This has also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong, which experienced a notable decrease in patient visits. The Hong Kong market is gradually moving towards stabilization in line with this trend. The Group has deliberately pivoted away from low-margin segments and remains focused on serving mid- and high-value customers, thereby ensuring the long-term sustainable profitability of the Group’s business.

The increase in revenue from Australia reflected a strong uptake of digital products driven by the digitalization trend in dental industry and anti-snoring products.

The increase in revenue in Others mainly represented the increase in revenue in Thailand, Singapore and Malaysia.

Notably, positive revenue growths were achieved in higher-margin regions such as Europe and Australia, whereas revenue declined in the relatively lower-margin business of MicroDental. This favorable geographical mix shift and the appreciation of foreign currencies against Hong Kong Dollars are expected to improve the Group’s overall margin percentage.

Sales Volumes (Number of Cases)

For the three months ended 31 March 2026, the total sales volumes of the Group increased by approximately 4.0% to approximately 720,000 cases (three months ended 31 March 2025: approximately 692,000 cases).

Digital Solution Cases

For the three months ended 31 March 2026, the Group’s digital solution cases (overseas and domestic) that are produced from its Mainland China, Thailand and Vietnam production facilities (which, for the avoidance of doubt, does not include digital solution cases produced in the Group’s non-Mainland China, non-Thailand and non-Vietnam production facilities or overseas/satellite dental laboratories) increased to approximately 294,712 cases reflecting an increase of 24.6% for the same period in 2025 (approximately 236,488 cases) as a result of our clients’ increased adoption of intra-oral scanners.

Average Selling Price

For the three months ended 31 March 2026, the average selling price of the Group’s dental prosthetic products across its markets was HK$1,273 per case (three months ended 31 March 2025: HK$1,188), representing an increase of approximately 7.2% mainly due to the appreciation of foreign currencies against Hong Kong Dollars.

Looking forward, the global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient

experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. The Group’s underlying fundamentals remain solid, and we are well positioned to capitalize on emerging opportunities going forward.

About Modern Dental Group

Modern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners and anti-snoring devices.

Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 35,000 customers.

NEW YORK, May 29, 2026 - (ACN Newswire) - Confimarket, backed and incubated by WebWise Capital, is pioneering confidential consensus discovery and information-aggregation infrastructure for institutional participants requiring strict privacy, robust market structures, and advanced financial workflows. Built on the Canton Network, the privacy-preserving market intelligence platform secured first place at the inaugural HackCanton Season 1 grand final, emerging victorious from a competitive global pool of more than 300 development teams across 15 countries.

Confimarket, a privacy-preserving prediction market built on Canton Network, has won first place at HackCanton Season 1 after advancing through a competitive field of more than 300 builders from over 15 countries.

The project was selected as the first-place winner following the grand final of HackCanton Season 1, an ecosystem hackathon organized by AppsFactory and focused on DeFi, RWA, DAO & Governance, and AI applications for Canton Network.

Confimarket is being developed as a prediction market for serious capital and demanding participants. Its core thesis is that prediction markets become materially more valuable when users can participate without exposing sensitive strategy, intent, or positioning to the broader market.

Prediction markets have already shown their ability to aggregate information at scale. However, many high-value participants — including professional traders, institutions, analysts, and organizations with sensitive views — may be reluctant to participate in fully transparent public markets. Confimarket is designed around that gap: market-based information discovery with privacy-preserving participation, credible settlement, and infrastructure suitable for more advanced financial workflows.

"Prediction markets are one of the most important categories in crypto because they turn information, belief, and probability into tradable markets. But the next stage of the category requires better infrastructure for participants who cannot expose their strategies or positions publicly," said Alexander I, General Partner at WebWise Capital. "That is the opportunity we see with Confimarket: confidential prediction markets built for more serious capital, stronger market structure, and institutional-grade use cases."

Canton Network is a natural environment for this model because it combines privacy, interoperability, and an architecture designed for synchronized financial markets. Canton describes itself as the first privacy-enabled open blockchain network, built to preserve privacy while allowing participants to exchange data and value across connected applications.

Canton Network has also been attracting prominent financial institutions and ecosystem participants. Official Canton materials list organizations such as J.P. Morgan, Goldman Sachs, BNY, BNP Paribas, Bank of America, and others in the broader ecosystem. For Confimarket, this makes Canton a strategically relevant foundation: the network is designed around privacy-preserving financial infrastructure rather than general-purpose public-chain transparency.

During HackCanton Season 1, Confimarket refined its product thesis, shipped core functionality, gathered user feedback, and strengthened the architecture behind the platform. The team used the hackathon as an early proving ground for confidential prediction market workflows on Canton Network, with a focus on market creation, trading logic, settlement flows, and the user experience required to make prediction markets accessible to higher-value participants.

The hackathon win represents an early ecosystem validation signal for Confimarket as the project moves from prototype development toward product readiness. The grand final and judging process provided feedback from Canton ecosystem leaders, venture investors, infrastructure companies, and industry participants.

Projects at HackCanton Season 1 were evaluated by representatives from the Canton Foundation as well as venture and industry participants including DWF Ventures, LongHash, Scytale Digital, Jsquare VC, Quantstamp, and Chainlink Labs.

Following the hackathon, Confimarket is focused on completing its trading engine, improving the user interface and onboarding flow, preparing private beta access, and working toward liquidity and ecosystem partnerships. The team's next phase is centered on turning the hackathon-winning prototype into a product that can support real prediction market activity, privacy-preserving participation, and institutional-grade use cases.

Confimarket is also continuing to position itself within the Canton ecosystem as a prediction market layer for use cases where privacy, credible execution, and market-based forecasting are essential.

Follow Confimarket on X for product updates, ecosystem announcements, and launch news, or explore the live app at confimarket.io.

About Confimarket

Confimarket is a privacy-preserving prediction market built on Canton Network. The project is designed for participants who need confidential participation, stronger market structure, and infrastructure suitable for institutional-grade workflows. Confimarket is backed and incubated by WebWise Capital.

About WebWise Capital

WebWise Capital backs and incubates early-stage projects at the intersection of AI, Web3, fintech, and digital financial infrastructure.

Media contact
Brand: Confimarket
Contact: Media team
Website: https://confimarket.io/

Toronto, Ontario--(ACN Newswire - May 28, 2026) - Radisson Mining Resources Inc. (TSXV: RDS) (OTCQX: RMRDF) ("Radisson" or the "Company") is pleased to announce that it has closed its previously announced "bought deal" private placement pursuant to which the Company issued a total of 18,115,797 Class A common shares of the Company that each qualify as "flow-through shares" (within the meaning of subsection 66(15) of the Income Tax Act (Canada)) as part of a charity arrangement (the "FT Shares"), at a price of $1.38 per FT Share, for aggregate gross proceeds of $24,999,800 (the "Offering"). The 18,115,797 FT Shares issued under the Offering include 2,174,000 FT Shares issued and sold pursuant to the full exercise of the option granted by the Company to the Underwriters.

Matt Manson, President and CEO: "We are very grateful for the strong support demonstrated for this financing from existing and new shareholders. In October 2025, we expanded our successful deep, step-out drill program at the O'Brien Gold Project to what will be an eventual 140,000 metres with up to eight drill rigs. The drill program is ongoing, and in March of this year we demonstrated its value with an interim, and meaningful, increase in the estimate of the Project's mineral resources. With this financing completed, we can now (i) plan the expansion and extension of our drilling through to the end of 2027, (ii) manage our capital resources more efficiently with our "flow-through" eligible exploration expenditures, and (iii) establish a strong treasury to support project development activities and project de-risking. In particular, our step-out drilling ambition is to go deeper. Until now, our exploration horizon has been to a floor of 2 kilometers depth. Results to date indicate extensive gold mineralization with good continuity beneath the former mine and the current mineral resources to at least 1.9 kilometers depth (see Radisson news release dated April 30, 2026). Given the character of neighboring gold deposits and the wealth of mining infrastructure within or close to the O'Brien Gold Project, we now intend to extend our exploration to a depth of 2.5 kilometers with new deep drilling and directional wedging. We believe that O'Brien gold mineralization has the potential to extend to at least these depths, that such mineralization offers the potential for significant new mineral resources in excess of our current exploration target, and that these mineral resources might be reasonably expected to be developed."

The Company will use an amount equal to the gross proceeds from the sale of the FT Shares, pursuant to the provisions in the Income Tax Act (Canada) (the "Tax Act"), to incur eligible "Canadian exploration expenses" that qualify as "flow-through mining expenditures" (as both terms are defined in the Tax Act) (the "Qualifying Expenditures") in connection with the exploration of the O'Brien Gold Project, including deep drilling beyond the scope of the current program, on or before December 31, 2027. The Company will renounce all such Qualifying Expenditures in favour of the subscribers of the FT Shares effective December 31, 2026. In the event the Company is unable to renounce Qualifying Expenditures effective on or prior to December 31, 2026 for each FT Share purchased in an aggregate amount not less than the gross proceeds raised from the issue of the FT Shares, the Company will indemnify each FT Share subscriber, as applicable, for the additional taxes payable by such subscriber as a result of the Company's failure to renounce the Qualifying Expenditures as agreed.

The Offering was completed pursuant to an underwriting agreement dated May 28, 2026 between the Company and a syndicate of underwriters led by ATB Cormark Capital Markets (collectively, the "Underwriters"). In consideration for the services provided to the Company in connection with the Offering, the Underwriters received an aggregate cash commission equal to $1,316,792.99, representing (i) 6% of the gross proceeds of the Offering with respect to the FT Shares sold to purchasers not on the President's List, and (ii) 3% of the gross proceeds of the Offering with respect to the FT Shares sold to purchasers on the President's List, provided that no commission was paid with respect to certain U.S. Purchasers under the President's List (the "Cash Commission"). The Cash Commission was paid by the Company with existing cash on hand.

The Offering remains subject to the final acceptance of the TSX Venture Exchange.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 - Prospectus Exemptions ("NI 45-106"), the FT Shares have been offered for sale to purchasers resident in all provinces of Canada pursuant to the listed issuer financing exemption under Part 5A of NI 45-106, as amended by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the "Listed Issuer Financing Exemption"). The FT Shares issued under the Offering to purchasers resident in Canada under the Listed Issuer Financing Exemption will not be subject to a hold period pursuant to applicable Canadian securities laws.

An amended offering document related to the Offering and the use by the Company of the Listed Issuer Financing Exemption can be accessed under the Company's profile on SEDAR+ at www.sedarplus.ca and on the Company's website at www.radissonmining.com.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any of the securities laws of any state of the United States, and are not being offered or sold within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an exemption from the registration requirements of the U.S. Securities Act and any applicable securities laws of any state of the United States.

Qualified Persons 

Disclosure of a scientific or technical nature in this news release was prepared under the supervision of Mr. Richard Nieminen, P.Geo, (QC), a geological consultant for the Company and a Qualified Person for purposes of National Instrument 43-101 - Standards of Disclosure for Mineral Projects. Mr. Nieminen is independent of the Company and the O'Brien Gold Project.

About Radisson Mining

The Company is a gold exploration company focused on its 100% owned O'Brien Gold Project ("O'Brien" or the "Project"), located in the Bousquet-Cadillac mining camp along the world-renowned Larder-Lake-Cadillac Break in Abitibi, Québec. A July 2025 PEA described a low cost and high value project with an 11-year mine life and significant upside potential based on the use of existing regional infrastructure. Indicated Mineral Resources are estimated at 0.63 Moz (3.49 Mt at 5.59 g/t Au), with additional Inferred Mineral Resources estimated at 1.69 Moz (10.37 Mt at 5.08 g/t Au).

Please see the technical report titled "O'Brien Gold Project NI 43-101 Technical Report and Preliminary Economic Assessment, Québec, Canada" effective June 27, 2025 (the "PEA"), Radisson's news release dated March 2, 2026 titled "With Step-Out Drilling Continuing, Radisson Demonstrates Meaningful Resource Growth at O'Brien with an Updated Mineral Resource Estimate" and other filings made with Canadian securities regulatory authorities available at www.sedarplus.ca for further details and assumptions relating to the Project. The PEA is preliminary in nature, it includes inferred mineral resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as mineral reserves, and there is no certainty that the PEA will be realized.

The Company's head and registered office is located at 50 du Petit-Canada Street, Rouyn-Noranda, Québec J0Y 1C0. The Class A common shares of the Company are listed on the TSX-V under the symbol "RDS" and on the OTCQX under the symbol "RMRDF".

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Forward-Looking Statements

This news release may contain forward-looking statements and forward-looking information within the meaning of applicable Canadian securities legislation (collectively, "forward-looking information"), including, but not limited to, the Offering (including the tax treatment of the FT Shares, the timing to renounce all Qualifying Expenditures in favour of the subscribers and the use of proceeds of the Offering), statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions and the Company's anticipated work programs. Often, but not always, forward-looking information can be identified by the use of words and phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information reflects the Company's beliefs and assumptions based on information available at the time such statements were made. Actual results or events may differ from those predicted in forward-looking information. All of the Company's forward-looking information is qualified by the assumptions that are stated or inherent in such forward-looking information, including the assumptions listed below.

Although the Company believes that the assumptions underlying the forward-looking information contained in this news release are reasonable, this list is not exhaustive of the factors that may affect any forward-looking information. The key assumptions that have been made in connection with forward-looking information include the following: that the Company will use the proceeds of the Offering as anticipated; and that the Company will receive all necessary approvals in respect of the Offering.

Forward-looking information involves known and unknown risks, future events, conditions, uncertainties, and other factors which may cause the actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by forward-looking information. Such factors include, among others, general business, economic, competitive, political and social uncertainties; that the Company will not use the proceeds of the Offering as anticipated; that the Company will not receive all necessary approvals in respect of the Offering; market volatility; the state of the financial markets for the Company's securities; the speculative nature of mineral exploration and development; fluctuating commodity prices; the future tax treatment of the FT Shares; competitive risks; costs of exploration; the actual results of current exploration activities; risks and uncertainties related to the ability to obtain or maintain necessary licenses, permits or surface rights; errors in geological modelling; conclusions of economic evaluations; changes in project parameters as plans continue to be refined; exploration results not being consistent with the Company's expectations; the supply and demand for, deliveries of, and the future prices of commodities; accidents, labour disputes and other risks of the mining industry; the availability of qualified employees and contractors; political instability; the impact of value of the Canadian dollar and U.S. dollar, foreign exchange rates on costs and financial results; market competition; changes in taxation rates or policies; technical difficulties in connection with mining activities; changes in environmental regulation; environmental compliance issues; delays in obtaining governmental approvals or financing; and other risks of the mining industry.

Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Readers should consider reviewing the detailed risk discussion in the sections entitled "Risks and Uncertainties related to Exploration" and "Risks Related to Financing and Development" in the management discussion & analysis for the year ended December 31, 2025, the financial statements of the Company, and other public disclosure of the Company, all of which are available on SEDAR+ under Radisson's issuer profile, for a fuller understanding of the risks and uncertainties that affect the Company's business and operations. Forward-looking information contained herein is given as of the date of this news release and the Company disclaims any obligation to update any forward-looking information, whether as a result of new information, future events, or results, except as may be required by applicable securities laws. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information.

Not for distribution to United States newswire services or for dissemination in the United States

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299213